Company Description Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing.
Proceeds Purposes The proceeds will support ongoing development of Aerpio’s pipeline, including AKB-9778, which is entering Phase 1b/2a for the treatment of diabetic macular edema (DME).